CombiMatrix Announces Contract With Blue Cross and Blue Shield Kansas City
12 Noviembre 2013 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that it has entered into a contractual agreement with the provider
network of Blue Cross and Blue Shield of Kansas City (Blue KC) for
coverage of its diagnostic laboratory services.
The agreement with Blue KC, the largest not-for-profit health
insurer in Missouri, provides access to CombiMatrix's suite of
molecular diagnostic solutions and comprehensive clinical
support—specializing in prenatal, miscarriage and pediatric
healthcare—to more than 800,000 members.
About Blue Cross and Blue Shield of Kansas
City
Blue Cross and Blue Shield of Kansas City, the largest
not-for-profit health insurer in Missouri and the only
not-for-profit commercial health insurer in Kansas City, has been
part of the Kansas City community since 1938. Ranked by J.D. Power
and Associates in 2013 as "Highest Member Satisfaction among
Commercial Health Plans in the Heartland Region, Two Years in a
Row," Blue Cross and Blue Shield of Kansas City provides health
coverage services to more than one million residents in the greater
Kansas City area, including Johnson and Wyandotte counties in
Kansas and 30 counties in Northwest Missouri. Its mission: to use
its role as the area's leading health insurer to provide affordable
access to health care and to improve the health and wellness of its
members. Blue Cross and Blue Shield of Kansas City is an
independent licensee of the Blue Cross and Blue Shield Association.
For more information on the company, visit its website at
BlueKC.com.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of genetic abnormalities at the DNA
level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing
advanced technologies, including microarray, FISH, PCR and G-Band
chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and
include, but are not limited to, statements regarding the access to
our services for Blue KC members. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties
referred to above include, but are not limited to: use of our
services by Blue KC members; market acceptance of CMA as a
preferred method over karyotyping; the rate of transition to CMA
from karyotyping; our ability to successfully expand the base of
our customers and strategic partners, add to the menu of our
diagnostic tests in both of our primary markets, develop and
introduce new tests and related reports, optimize the
reimbursements received for our testing services, and increase
operating margins by improving overall productivity and expanding
sales volumes; our ability to successfully accelerate sales, allow
access to samples earlier in the testing continuum, steadily
increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets;
changes in demand for our future products; legislative, regulatory
and competitive developments; general economic conditions; and
various other factors. Further information on potential
factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in
other filings with the Securities and Exchange Commission. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason, except as required by
law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024